Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-020-0148-4, published online 27 March 2020
Since the publication of this article,1 we noticed a minor mistake in the reference that needs to be corrected.
To support the clinical manifestation “metabolic acidosis” in the COVID-19, in the fifth sentence of paragraph one, we cited an inappropriate reference 4 “Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 395, 497-506, (2020)” which needs to be replaced with Diagnosis and Treatment Protocol for COVID-19 (Trial Version 5) published by National Health Commission of the People’s Republic of China.
The key messages of the article are not affected by this correction. We apologize for this inadvertent mistake.
Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig. Transduct. Target Ther. 5, 33, https://doi.org/10.1038/s41392-020-0148-4 (2020).
About this article
Cite this article
Tan, L., Wang, Q., Zhang, D. et al. Correction: Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Sig Transduct Target Ther 5, 61 (2020). https://doi.org/10.1038/s41392-020-0159-1
Scientific Reports (2021)
Clinical Chemistry and Laboratory Medicine (CCLM) (2021)
Single-Cell RNA Sequencing Analysis of the Immunometabolic Rewiring and Immunopathogenesis of Coronavirus Disease 2019
Frontiers in Immunology (2021)
Expert Review of Clinical Immunology (2021)
Lymphocyte-to-C-reactive protein ratio may serve as an effective biomarker to determine COVID-19 disease severity
Turkish Journal of Biochemistry (2021)